Safety Concerns About Saltz Regimen Were Statistical Artifact, ODAC Finds.
AACI: von Eschenbach “Wonderful Choice” For NCI Director, Knows How Centers Work. Cancer Centers Pleased With Bush Choice For NCI.
Campus-Dweller Rabson Finds Comfort In NIH Security.
Endostatin Enters Phase II Trial For Neuroendocrine Tumors.
Siemens To Provide Technology To DxTx For Lung Cancer Detection.
Myriad In Partnership To Market Products.
Computer-Aided Detection Approved For Mammograms.
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”









